Vivani Medical

Yahoo Finance • 2 months ago

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 r... Full story

Yahoo Finance • 3 months ago

Vivani Medical, Inc. Announces Closing of Common Stock Offering

ALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the clo... Full story

Yahoo Finance • 3 months ago

Vivani Medical prices $16M offering at $1.62 per share

* Clinical-stage biopharmaceutical company Vivani Medical (NASDAQ:VANI [https://seekingalpha.com/symbol/VANI]) priced [https://seekingalpha.com/pr/20279638-vivani-medical-inc-announces-pricing-of-common-stock-offering] a registered direc... Full story

Yahoo Finance • 3 months ago

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pri... Full story

Yahoo Finance • 3 months ago

Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off

ALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that th... Full story

Yahoo Finance • 4 months ago

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025

ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that i... Full story

Yahoo Finance • 4 months ago

Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifie... Full story

Yahoo Finance • 4 months ago

Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream

MIAMI, Sept. 23, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifie... Full story

Yahoo Finance • 4 months ago

Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent’s ne... Full story

Yahoo Finance • 4 months ago

September 2025's Promising Penny Stock Opportunities

As the U.S. stock market experiences fluctuations, with major indices like the Dow Jones and S&P 500 recently hitting record highs before turning lower, investors are closely monitoring economic indicators such as job reports and potential... Full story

Yahoo Finance • 5 months ago

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CE... Full story

Yahoo Finance • 5 months ago

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity f... Full story

Yahoo Finance • 5 months ago

Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study’s primary objectives New NPM... Full story

Yahoo Finance • 5 months ago

EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data

Vivani Medical Inc. (NASDAQ:VANI) on Tuesday reported results from the LIBERATE-1 Phase 1 study of the exenatide GLP-1 implant NPM-115, representing the first-in-human test of the company's proprietary NanoPortal implant technology. Exena... Full story

Yahoo Finance • 8 months ago

Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders

Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion® Visual Cortical Prosthesis System to provi... Full story

Yahoo Finance • 8 months ago

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025 An... Full story

Yahoo Finance • 8 months ago

Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO... Full story

Yahoo Finance • 9 months ago

Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D. to discuss the Company’s LIBERATE-1 clinical trial fr... Full story

Yahoo Finance • 9 months ago

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and... Full story

Yahoo Finance • 10 months ago

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) pre... Full story